Precision Therapeutics, operating under the name Predictive Oncology, leverages advanced technologies to enhance drug discovery and development processes. Central to their approach is a proprietary platform that integrates artificial intelligence (AI) with a vast biobank of over 150,000 tumor samples. This combination allows for high-confidence predictions of drug responses, addressing the complexities of tumor heterogeneity and improving the likelihood of successful clinical outcomes. Their innovative 3D tumor models further replicate the intricate human organ microenvironment, providing a more accurate testing platform that correlates closely with clinical responses.

In addition to their drug discovery capabilities, Predictive Oncology offers a comprehensive suite of clinical research services. Their CLIA-certified laboratory supports a range of pharmaceutical and biomarker research, including the development of patient-centric ex vivo models and the validation of biomarkers through various advanced techniques such as genomics and proteomics. The company also provides robust biorepository services, ensuring meticulous specimen management and continuous monitoring. By combining these technologies and services, Predictive Oncology aims to personalize cancer therapies and optimize treatment plans for better patient outcomes.

United States

Our mission at Predictive Oncology is to change the landscape of oncology drug discovery and enable the development of more effective therapies in the treatment of cancer.  By harnessing the power of machine learning, scientific rigor and biologics, we can improve the probability of success and advance drug compounds with a higher degree of confidence. 

We invite you to follow us to stay up-to-date about our latest developments.

Precision Therapeutics(Predictive Oncology)

Company Details